FDA Panel: Split Decision for Descovy in PrEP

– Solid yes for men and transgender women, but consensus missing for cisgender women An FDA advisory panel overwhelmingly voted 16-2 to recommend Descovy, the fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF), as pre-exposure prophylaxis...

Henry House – One Woman’s Journey

By Bri Silva & Julie Dowling, Co-Facilitators of This is Us, a support group for women living with or affected by HIV Henry House is the place she went to die. It was a place that many, over the years, would also go to die in order to spare those they loved the...

Welcome to our new Executive Director

On behalf of the Board of Directors, I am happy to announce that Dana Van Gorder will serve as the new Executive Director of The Spahr Center, effective immediately. Many of you have come to know Dana since he stepped in to this role on an interim basis on February...

The Spahr Center lobbies for PrEP and PEP

Andy Fyne, Testing & Prevention Manager PrEP and PEP are exciting and important strategies for helping us to prevent new HIV infections.  But both medically-based prevention strategies are suffering from alarmingly low levels of use.  The Spahr Center is engaging...

PrEP Could Become Over-the-Counter Drug In California

A bill just approved by the California State Senate would make Truvada, the HIV drug that’s been found to be effective at preventing new HIV infections, available for over-the-counter use for 30 days. The bill is aimed at HIV-negative gay and bisexual men of...